Skip to main content
SpringerLink
Log in

Early Ketamine to Treat Refractory Status Epilepticus

  • Practical Pearl
  • Published:
Neurocritical Care Aims and scope Submit manuscript

Abstract

Background

Management of refractory status epilepticus (SE) involves administration of intravenous γ-aminobutyric acid (GABAA) receptor agonists, such as benzodiazepines, barbiturates, or propofol. Animal models suggest that reductions in synaptic GABAA receptors may cause these drugs to become less effective as the duration of SE increases. This may explain the large doses that are commonly required to control seizures, which in turn contributes to a high incidence of complications, including hypotension and the need for vasopressors. In contrast, expression of excitatory N-methyl-d-aspartate (NMDA) receptors increases with prolonged SE and their stimulation by glutamate may propagate seizure activity. Ketamine is a NMDA-receptor antagonist that is considered promising as treatment for refractory SE. Compared with other anaesthetic drugs, ketamine produces less hypotension.

Methods

This report describes a patient who developed worsening hypotension with escalating doses of midazolam and propofol in the context of non-convulsive SE. He was therefore treated with ketamine within hours of being diagnosed.

Results

Ketamine was immediately efficacious at reducing the frequency, amplitude, and duration of seizures. The dose was rapidly titrated upwards using quantitative continuous EEG monitoring, until seizures were completely abolished. SE did not recur with weaning of sedatives and he went on to have an excellent recovery. A small number of previous reports have found ketamine to abort late SE. In most cases, ketamine was administered several days into the course, and outcomes were poor even though seizures were controlled.

Conclusion

Larger series and phase I clinical trial(s) of ketamine for treatment of refractory SE seem warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011;10:922–30.

    Article  PubMed  Google Scholar 

  2. Claassen J, Hiersch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002;43:146–53.

    Article  PubMed  CAS  Google Scholar 

  3. Goodkin HP, Yeh JL, Kapur J. Status epilepticus increases the intracellular accumulation of GABAA receptors. J Neurol. 2005;25:5511–20.

    CAS  Google Scholar 

  4. Mazarati AM, Wasterlain CG. N-methyl-d-aspartate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett. 1999;265:187–90.

    Article  PubMed  CAS  Google Scholar 

  5. Kapur J, Lothman EW. NMDA receptor activation mediates the loss of GABAergic inhibition induced by recurrent seizures. Epilepsy Res. 1990;5:103–11.

    Article  PubMed  CAS  Google Scholar 

  6. Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res. 2000;42:117–42.

    Article  PubMed  CAS  Google Scholar 

  7. Walker MC, Howard RS, Smith SJ, et al. Diagnosis and treatment of status epilepticus on a neurological intensive care unit. Q J Med. 1996;89:913–20.

    CAS  Google Scholar 

  8. Kofke WA, Bloom MJ, Van Cott A, Brenner RP. Electrographic tachyphylaxis to etomidate and ketamine used for refractory status epilepticus controlled with isoflurane. J Neurosurg Anesthesiol. 1997;9:269–72.

    Article  PubMed  CAS  Google Scholar 

  9. Sheth RD, Gidal BE. Refractory status epilepticus: response to ketamine. Neurology. 1998;51:1765–6.

    PubMed  CAS  Google Scholar 

  10. Nathan B, Smith TL, Bleck TB. The use of ketamine in the treatment of refractory status epilepticus. Neurology. 2002;3:A197.

    Google Scholar 

  11. Ubogu EE, Sagar SM, Lerner AJ, et al. Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. Epilepsy Behav. 2003;4:70–5.

    Article  PubMed  Google Scholar 

  12. Pruss H, Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res. 2008;82:219–22.

    Article  PubMed  Google Scholar 

  13. Hsieh CY, Sung PS, Tsai JJ, Huang CW. Terminating prolonged refractory status epilepticus using ketamine. Clin Neuropharm. 2010;33:165–7.

    Article  Google Scholar 

  14. Yeh PS, Shen HN, Chen TY. Oral ketamine controlled refractory nonconvulsive status epilepticus in an elderly patient. Seizure. 2011;20:723–6.

    Article  PubMed  Google Scholar 

  15. Stewart CP, Otsubo H, Ochi A, et al. Seizure identification in the ICU using quantitative EEG displays. Neurology. 2010;75:1501–8.

    Article  PubMed  CAS  Google Scholar 

  16. Ko SB, Ortega-Gutierrez S, Choi HA, et al. Status epilepticus-induced hyperemia and brain tissue hypoxia after cardiac arrest. Arch Neurol. 2011;68:1323–6.

    Article  PubMed  Google Scholar 

  17. Stewart LS, Persinger MA. Ketamine prevents learning impairment when administered immediately after status epilepticus onset. Epilepsy Behav. 2001;2:585–91.

    Article  PubMed  Google Scholar 

  18. Martin BS, Kapur J. A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation. Epilepsia. 2008;49:248–55.

    Article  PubMed  CAS  Google Scholar 

  19. Iyer VN, Hoel R, Rabinstein AA. Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med. 2009;37:3024–30.

    Article  PubMed  CAS  Google Scholar 

  20. Rossetti AO, Reichhart MD, Schaller MD, et al. Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia. 2004;45:757–63.

    Article  PubMed  CAS  Google Scholar 

  21. Vasile B, Rasulo F, Candiani A, Latronico N. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003;29:1417–25.

    Article  PubMed  Google Scholar 

  22. Mewasingh LD, Skhara T, Aeby A, et al. Oral ketamine in paediatric non-convulsive status epilepticus. Seizure. 2003;12:483–9.

    Article  PubMed  CAS  Google Scholar 

  23. Kramer U, Shorer Z, Ben-Zeev B, et al. Severe refractory status epilepticus owing to presumed encephalitis. J Child Neurol. 2005;20:184–7.

    PubMed  Google Scholar 

  24. Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain ischaemia is mainly be reversed uptake. Nature. 2000;403:316–21.

    Article  PubMed  CAS  Google Scholar 

  25. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091–8.

    Article  PubMed  CAS  Google Scholar 

  26. Benarroch EE. NMDA receptors: recent insights and clinical correlations. Neurology. 2011;76:1750–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

The author acknowledges Dr. Neelan Pillay, who assisted with timely cEEG interpretation in this patient.

Author information

Authors and Affiliations

  1. Department of Critical Care Medicine, University of Calgary, ICU Administration, Ground Floor, McCaig Tower, 3134 Hospital Dr NW, Calgary, AB, T2N 2T9, Canada

    Andreas H. Kramer

  2. Department of Clinical Neurosciences, University of Calgary, ICU Administration, Ground Floor, McCaig Tower, 3134 Hospital Dr NW, Calgary, AB, T2N 2T9, Canada

    Andreas H. Kramer

Authors
  1. Andreas H. Kramer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas H. Kramer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kramer, A.H. Early Ketamine to Treat Refractory Status Epilepticus. Neurocrit Care 16, 299–305 (2012). https://doi.org/10.1007/s12028-011-9668-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-011-9668-7

Keywords

Search

Navigation